EXONDYS 51 Drug Patent Profile

Which patents cover Exondys 51, and when can generic versions of Exondys 51 launch?

Exondys 51 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and twenty-nine patent family members in twenty-three countries.

The generic ingredient in EXONDYS 51 is eteplirsen. One supplier is listed for this compound. Additional details are available on the eteplirsen profile page.

DrugPatentWatch^® Generic Entry Outlook for Exondys 51

Exondys 51 was eligible for patent challenges on September 19, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 2, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EXONDYS 51

International Patents:	129
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXONDYS 51
What excipients (inactive ingredients) are in EXONDYS 51?	EXONDYS 51 excipients list
DailyMed Link:	EXONDYS 51 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXONDYS 51

NDA:

206488

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EXONDYS 51

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sarepta Therapeutics	Phase 3
Sarepta Therapeutics, Inc.	Phase 3
Catabasis Pharmaceuticals	Phase 1/Phase 2

See all EXONDYS 51 clinical trials

Pharmacology for EXONDYS 51

Drug Class

Antisense Oligonucleotide

US Patents and Regulatory Information for EXONDYS 51

EXONDYS 51 is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes			Y
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes

Expired US Patents for EXONDYS 51

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016

EU/EMA Drug Approvals for EXONDYS 51

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AVI Biopharma International Ltd	Exondys	eteplirsen	EMEA/H/C/004355Treatment of Duchenne muscular dystrophy.	Refused	no	no	yes		2018-12-06

International Patents for EXONDYS 51

See the table below for patents covering EXONDYS 51 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014233456
Australia	2019203505
Australia	2020260492

EXONDYS 51 (eteplirsen) market dynamics and financial trajectory: sales trends, payer/market access drivers, and exclusivity-driven competitive risk

Last updated: June 26, 2026

Executive summary

• EXONDYS 51 (eteplirsen) is a niche, high-cost dystrophin gene-skipping therapy for Duchenne muscular dystrophy (DMD) with confirmed DMD gene mutation amenable to exon 51 skipping. Demand is constrained by patient eligibility, high gross-to-net pressure, and continued dominance of the eteplirsen label as an exon-51-skipping option.
• The revenue trajectory is driven by: (1) treatable-prevalence growth and diagnosis rates for exon 51–skipping mutations, (2) uptake among neuromuscular centers, (3) contracting and utilization management outcomes, and (4) ongoing payer scrutiny of cost-effectiveness versus competing dystrophin-restoration strategies.
• Competitive risk is structural, not near-term: the main threats to market share are future exon-skipping entrants and alternative dystrophin-restoration modalities (including other gene therapies and systemic RNA approaches) rather than immediate FDA-approved direct substitutes in the same exon 51 niche.
• Financial outcomes have historically been characterized by large gross prices and meaningful net price discounting, with revenue growth linked to incremental patient starts rather than broad market penetration.

How is EXONDYS 51 sold and priced in the US DMD market

EXONDYS 51 is priced as a specialized, high-cost infusion biologic. Its commercial model is shaped by payer design centered on specialty drug contracting and utilization management.

Featured snippet answer: EXONDYS 51 sells primarily through specialty pharmacies and direct-to-provider channel models under managed-care contracts, with payer eligibility tied to DMD exon 51-skipping mutation confirmation and DMD stage criteria.

What determines net price for EXONDYS 51

Key drivers of gross-to-net include:

• Prior authorization and documentation requirements (mutation confirmation, dystrophin-related phenotype, and treatment eligibility).
• Coverage policies that restrict use to confirmed exon 51-skipping mutations.
• Contracting structures that vary by plan and channel (rebates and patient access guarantees).
• Site of care and infusion reimbursement economics, affecting payer willingness to cover.

What payers evaluate during coverage

Typical payer checkpoints for DMD exon-skipping therapies include:

• Genetic testing showing amenable mutation for exon 51 skipping.
• Baseline function and disease stage.
• Lack of contraindications and adherence to labeling criteria.
• Treatment continuation criteria after an initial assessment window.

Specialty distribution model

EXONDYS 51 is handled as a specialty infusion therapy:

• Distribution is typically managed through specialty pharmacy networks and authorized infuser entities.
• Commercial execution depends on neuromuscular center prescribing, infusion capacity, and payer approval timelines.

Which patient eligibility factors limit EXONDYS 51 demand in Duchenne muscular dystrophy

EXONDYS 51’s market is limited by the fraction of DMD patients with mutations amenable to exon 51 skipping and by diagnosis timing.

What “exon 51 amenable” means commercially

• Patient identification depends on DMD mutation profiling at diagnosis and during disease characterization.
• Demand scales with the effectiveness of genetic screening programs and the speed at which clinicians translate genetic results into exon-skipping candidacy.

Diagnosis and referral dynamics

• Neuromuscular specialists drive conversion from genetic eligibility to therapy initiation.
• Real-world use is affected by regional capacity for gene-skipping infusion logistics and by payer approval throughput.

Disease stage and persistence

• Continued use depends on payer coverage renewal and clinician determination of clinical benefit within label-consistent time frames.
• Discontinuation risk rises if payers narrow coverage based on response criteria or if patients progress outside coverage thresholds.

What are the main market dynamics affecting EXONDYS 51 sales growth

EXONDYS 51 sales behave like a specialty, concentrated product: growth comes primarily from incremental patient starts and persistence rather than switching from broader indications.

Demand drivers

• Expanded diagnosis and genetic testing uptake in pediatric and early DMD care settings.
• Increased clinician familiarity with exon-skipping workflows and infusion scheduling.
• Contracting improvements that reduce time-to-treatment.

Headwinds

• Payer pressure on expensive therapies increases.
• Health technology assessment frameworks and budget impact scrutiny can delay approvals.
• Competitive alternatives that change clinical standard of care can reduce new starts even if existing patients remain on therapy.

How does EXONDYS 51 revenue scale with patient starts and treatment persistence

For high-cost, label-restricted therapies, sales are usually a function of:

• Number of treated patients.
• Average duration on therapy (persistence).
• Contracted net price realized after rebates and coverage terms.

Operational pattern: If starts rise but persistence falls due to discontinuation, net revenue can stagnate even as eligibility increases.

What typically determines persistence

• Reauthorization policies by payers.
• Clinician assessment of functional metrics and clinical response expectations.
• Patient tolerance and infusion logistics.

What affects time-to-therapy

• Payer authorization turnaround.
• Documentation completeness (genetic test results, clinical documentation).
• Coverage denials and appeals cycles.

Who are the main competitors to EXONDYS 51 and how do they affect market share

EXONDYS 51’s closest competitive set is other DMD dystrophin-restoration approaches targeting overlapping patient populations, plus broader gene or RNA strategies that could reduce demand for exon-skipping.

Competition map by therapy class

• Exon-skipping RNA therapies: Therapies for other exons (not direct substitutes for exon 51, but compete for the same limited DMD infusion budget).
• Gene transfer / other gene therapies: Potential future displacement if outcomes and durability prove superior and coverage improves.
• Non exon-51 alternatives: May attract patients regardless of exon 51 candidacy, but generally do not directly substitute for confirmed exon 51 amenability.

Competitive implications for sales

• The key risk is not immediate within-label substitution, but clinical and payer preference shifts if competing modalities demonstrate better durability, dosing convenience, or stronger endpoints.

When does EXONDYS 51 face exclusivity or patent expiration risk that could impact sales

For this therapy, exclusivity and patent duration matter because biosimilar or generic-like substitutes are generally not a direct analog to small-molecule generics. The competitive pathway would depend on:

• Patent estates covering sequence, formulation, methods of use, and manufacturing.
• Regulatory pathway viability for an intended similar product under the relevant biologics framework.

Business relevance: Sales durability is primarily an IP and regulatory-access question rather than a simple chemistry patent question.

What typically extends commercial exclusivity

• Formulation and dosing regimen patents.
• Manufacturing and process patents.
• Method-of-use patents tied to exon skipping in DMD populations and patient eligibility markers.

(Patent timing specifics require structured Orange Book and patent list review; those data were not provided in the prompt.)

How strong is the patent estate for EXONDYS 51 as a sales shield

A therapy like EXONDYS 51 usually has a layered protection stack:

• Active sequence-related claims.
• Delivery and formulation approaches.
• Use claims for exon-skipping therapy in DMD with defined genetic eligibility.
• Manufacturing-process claims that can inhibit “copying” even when the active molecule is known.

Commercial implication: IP strength affects:

• Expected entry timing of competing products.
• Litigation and licensing likelihood.
• Payer switching behavior if a competing product emerges.

What is the FDA status of EXONDYS 51 and how does it influence adoption

FDA approval and labeling scope determine the size of the treatable population and coverage defensibility.

Label-driven adoption

• Clinicians prescribe within labeled criteria.
• Payers align coverage to labeled eligibility, which can cap penetration even when patient interest is present.

Impact of evidentiary updates

• Any FDA communications tied to required endpoints, continuation criteria, or label expansions can change payer behavior.
• If evidence supports broader benefit or expanded subgroups, adoption can improve.

(Exact current FDA labeling version and any post-approval modifications were not provided in the prompt.)

What market access obstacles affect EXONDYS 51 coverage and utilization

Managed entry tools and utilization management can delay starts and lower realized revenue.

Common utilization management levers

• Prior authorization tied to genetic confirmation.
• Step edits requiring enrollment in disease registries or therapy-specific monitoring.
• Reauthorization based on clinical assessments.

Impact of site-of-care

• Infusion site economics can influence payer willingness to approve.
• Provider contracting can influence whether the drug is used quickly after approval.

Financial trajectory: what to expect from gross-to-net and payer pressure

The most meaningful financial signal for EXONDYS 51 is the gap between gross pricing and net realized revenue.

Key financial metrics that typically move

• Net revenue growth driven by patient starts.
• Gross-to-net pressure driven by rebates and contracting.
• Commercial expense as the product matures and payer scrutiny increases.

Revenue sensitivity

For niche specialty drugs, revenue is sensitive to:

• Patient count changes from eligibility and discontinuation.
• Contract renegotiations that modify realized net price.
• Any changes in payer coverage policies.

Key takeaways

• EXONDYS 51 operates in a constrained exon 51–amenable DMD niche, so sales scale primarily with treated patient count and persistence, not broad market penetration.
• Net revenue is the primary commercial battleground, driven by payer utilization management and contracting terms.
• Competitive threat is more likely to emerge from alternative dystrophin-restoration modalities and future exon-skipping entries rather than immediate direct substitution.
• Exclusivity and patent estate strength determine the long-term sales shield, with layered protection typically slowing competitive entry.
• The financial trajectory is most sensitive to payer coverage dynamics and incremental patient starts across neuromuscular centers.

FAQs

1. How do genetic testing workflows impact EXONDYS 51 initiation rates?
2. What payer utilization management criteria most often delay EXONDYS 51 prior authorization?
3. How does site of care affect net revenue and infusion reimbursement for EXONDYS 51?
4. Do other exon-skipping therapies meaningfully reduce EXONDYS 51 demand through budget substitution?
5. What indicators signal rising payer risk of coverage restriction for EXONDYS 51?

References (APA)

1. (No sources were provided in the prompt.)